SCMC Trial on KHE With KMP (V.2020)

A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)

Inclusion Criteria:

• Kaposiform Hemangioendotheliomas with Kasabach-Merritt Phenomenon
• 0 - 12 years of age at the time of study entry
• Male or female
• Consent of parents (or the person having parental authority in families)
• Signed and dated written informed consent

Exclusion Criteria:

• with hematological diseases
• with other solid tumors
• with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney
• dysfunction, and cardiopulmonary insufficiency
• with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment